Hollow ZnO Nanospheres Enhance Anticancer Immunity by Promoting CD4+ and CD8+ T Cell Populations In Vivo. Issue 38 (21st August 2017)

• Record Type: Journal Article
• Authors: Wang, Xiupeng; Li, Xia; Ito, Atsuo; Sogo, Yu; Watanabe, Yohei; Tsuji, Noriko M.
• Is Part Of: Small. Volume 13:Issue 38(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-08-21
• Subjects: cancer immunoadjuvant -- hollow structure -- ZnO nanospheres; Nanotechnology -- Periodicals; Nanoparticles -- Periodicals; Microtechnology -- Periodicals; 620.5
• DOI: 10.1002/smll.201701816
• Languages: English
• ISSNs: 1613-6810

Abstract

Abstract : Appropriate adjuvant aiding in generating robust anticancer immunity is crucial for cancer immunotherapy. Herein, hollow ZnO (HZnO) nanospheres are synthesized by a facile method using carbon nanospheres as the template. The HZnO nanospheres significantly promote the cellular uptake of a model antigen, and cytokine secretion by antigen‐presenting cells in vitro. HZnO loaded with ovalbumin and polyinosinic‐polycytidylic acid (poly(I:C)) inhibits cancer growth and metastasis to inguinal lymph node in a cancer cell challenge model. Moreover, HZnO loaded with autologous cancer antigens inhibits cancer cell growth in a cancer cell re‐challenge model. HZnO nanospheres significantly improve the CD4 + and/or CD8 + T cell population in splenocytes of mice in both cancer cell challenge model and re‐challenge model. The HZnO nanospheres can be used for cancer immunotherapy as adjuvant. Abstract : Hollow ZnO nanospheres significantly promote the cellular uptake of a model cancer antigen, increase the CD4 + and/or CD8 + T cell populations in splenocytes of mice, and improve anticancer immunity. Hollow ZnO nanospheres are promising as an adjuvant for cancer immununotherapy.